
## Federica Maione

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8516954/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature, 2017, 552, 116-120.	27.8	480
2	Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. Journal of Clinical Investigation, 2009, 119, 3356-72.	8.2	167
3	Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice. Journal of Clinical Investigation, 2012, 122, 1832-1848.	8.2	154
4	Nucleolin Targeting Impairs the Progression of Pancreatic Cancer and Promotes the Normalization of Tumor Vasculature. Cancer Research, 2016, 76, 7181-7193.	0.9	99
5	Proteomics-Based Metabolic Modeling Reveals That Fatty Acid Oxidation (FAO) Controls Endothelial Cell (EC) Permeability. Molecular and Cellular Proteomics, 2015, 14, 621-634.	3.8	85
6	Tumour growth inhibition and antiâ€metastatic activity of a mutated furinâ€resistant Semaphorin 3E isoform. EMBO Molecular Medicine, 2012, 4, 234-250.	6.9	82
7	APâ€2α and APâ€2γ regulate tumor progression via specific genetic programs. FASEB Journal, 2008, 22, 2702-2714.	0.5	69
8	Semaphorin 4A Exerts a Proangiogenic Effect by Enhancing Vascular Endothelial Growth Factor-A Expression in Macrophages. Journal of Immunology, 2012, 188, 4081-4092.	0.8	64
9	Increased Expression of α6 Integrin in Endothelial Cells Unveils a Proangiogenic Role for Basement Membrane. Cancer Research, 2010, 70, 5759-5769.	0.9	60
10	The cholesterol biosynthesis enzyme oxidosqualene cyclase is a new target to impair tumour angiogenesis and metastasis dissemination. Scientific Reports, 2015, 5, 9054.	3.3	56
11	SILAC-Based Proteomics of Human Primary Endothelial Cell Morphogenesis Unveils Tumor Angiogenic Markers. Molecular and Cellular Proteomics, 2013, 12, 3599-3611.	3.8	55
12	α-ketoglutarate dehydrogenase inhibition counteracts breast cancer-associated lung metastasis. Cell Death and Disease, 2018, 9, 756.	6.3	54
13	Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E353-9.	7.1	51
14	Neuropilin-1 Identifies a Subset of Bone Marrow Gr1â^' Monocytes That Can Induce Tumor Vessel Normalization and Inhibit Tumor Growth. Cancer Research, 2012, 72, 6371-6381.	0.9	51
15	Peptide-functionalized nanoparticles for selective targeting of pancreatic tumor. Journal of Controlled Release, 2014, 192, 29-39.	9.9	48
16	Semaphorins and tumor angiogenesis. Angiogenesis, 2009, 12, 187-193.	7.2	46
17	A rationally designed NRP1-independent superagonist SEMA3A mutant is an effective anticancer agent. Science Translational Medicine, 2018, 10, .	12.4	46
18	Class 3 semaphorins in cardiovascular development. Cell Adhesion and Migration, 2016, 10, 641-651.	2.7	40

Federica Maione

#	Article	IF	CITATIONS
19	Osteopontin binds ICOSL promoting tumor metastasis. Communications Biology, 2020, 3, 615.	4.4	39
20	Class 3 semaphorins: physiological vascular normalizing agents for anti ancer therapy. Journal of Internal Medicine, 2013, 273, 138-155.	6.0	37
21	Therapeutic Silencing of miR-214 Inhibits Tumor Progression in Multiple Mouse Models. Molecular Therapy, 2018, 26, 2008-2018.	8.2	26
22	CAR T cells targeting tumor endothelial marker CLEC14A inhibit tumor growth. JCI Insight, 2020, 5, .	5.0	23
23	Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity. Journal of Translational Medicine, 2016, 14, 119.	4.4	18
24	Multivalent cationic pseudopeptide polyplexes as a tool for cancer therapy. Oncotarget, 2017, 8, 90108-90122.	1.8	15
25	Sema3F (Semaphorin 3F) Selectively Drives an Extraembryonic Proangiogenic Program. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1710-1721.	2.4	12
26	Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibodyâ€â€œdecoy― strategy. International Journal of Cancer, 2018, 143, 1774-1785.	5.1	11
27	Tumor Angiogenesis: Methods to Analyze Tumor Vasculature and Vessel Normalization in Mouse Models of Cancer. Methods in Molecular Biology, 2015, 1267, 349-365.	0.9	9
28	Inducible T-Cell Costimulator Ligand Plays a Dual Role in Melanoma Metastasis upon Binding to Osteopontin or Inducible T-Cell Costimulator. Biomedicines, 2022, 10, 51.	3.2	9
29	Abstract 5723: Inactivation of DNA repair triggers neoantigen generation and impairs tumor growth. Cancer Research, 2018, 78, 5723-5723.	0.9	5
30	Abstract 828: Targeting theMEToncogene by concomitant inhibition of receptor and ligand by an antibody-†decoy' strategy. , 2018, , .		1
31	Abstract SY41-04: Targeting Semaphorin 3A: A new tool to normalize tumor vasculature and to overcome the evasive resistance to the anti-angiogenic therapy. , 2012, , .		0
32	Abstract 4807: Zoledronic acid overcomes the resistance to the anti-angiogenic therapy and normalizes tumor vessels by switching from a M2- to a M1-like macrophages phenotype in a mouse model of spontaneous cervical cancer. , 2014, , .		0
33	Abstract 15: Nucleolin-targeting NUCANT normalizes tumor vasculature and inhibits tumor growth and metastasis formation in mouse models of cancer. , 2014, , .		0
34	Abstract 3366: NCL targeting impairs the progression of pancreatic ductal adenocarcinoma and promotes tumor vessel normalization through Ang-2 inhibition. , 2016, , .		0
35	Abstract 3372: Semaphorin 3A normalizes the tumor vasculature and impairs tumor progression in a Nrp-1-independent manner. , 2016, , .		0
36	Abstract PR13: Inactivation of DNA repair triggers dynamic neoantigen evolution and impairs cancer growth. , 2017, , .		0

#	Article	IF	CITATIONS
37	Abstract 2743: Accumulation of predicted neoantigens by MMR deficiency triggered by temozolomide treatment of human colorectal cancer. , 2018, , .		0